BioCentury
ARTICLE | Financial News

ICOS, PDLI, SEPR added to NASDAQ-100

December 18, 2001 8:00 AM UTC

Icos (ICOS), a developer of treatments for erectile dysfunction and sepsis; antibody play Protein Design (PDLI); and chiral compound and active metabolite developer Sepracor (SEPR) will be added on Mo...